Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Obsidian Therapeutics, Inc.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06060613CT.gov Safety and Efficacy of OBX-115 in Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obx-115 (this asset) | Obsidian Therapeutics, Inc. | P1/2 | CCC · 48 |
| Cyclosporin A | Wyeth is now a wholly owned subsidiary of Pfizer | P4 | BB |
| Tacrolimus | Wyeth is now a wholly owned subsidiary of Pfizer | P4 | BB |
| Sirolimus | Wyeth is now a wholly owned subsidiary of Pfizer | P4 | BB |
| Difluoromethylornithine | University of Wisconsin, Madison | P2 | B |
| Trastuzumab | Cancer Research UK | P2/3 | B |
| Axitinib | Pfizer | P2 | B |
| Imatinib | M.D. Anderson Cancer Center | P2 | B |
| Pertuzumab | Cancer Research UK | P2/3 | B |
+16 more in the Skin Neoplasm cohort
Other indications for Obx-115
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Melanoma | — | P1/2 | CCC · 48 |
| Melanoma | — | P1/2 | CC · 46 |
| Neoplasm | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obx-115 in Skin Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obx-115-skin-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →